A Study to Evaluate the Effect of Food on Levofloxacin Pharmacokinetics From an Oral Solution Formulation
A Study to Evaluate the Effect of Food on Levofloxacin Pharmacokinetics From an Oral Solution Formulation
The main purpose of the study was to evaluate the effect of food on the single-dose
 pharmacokinetics of an oral solution of levofloxacin.
In this single-dose study conducted at a single center, the effect of food on the
 pharmacokinetics of levofloxacin was studied in 24 healthy men and women aged 18 to 55 years
 old. Subjects were assigned different treatments based on chance; both the researcher and the
 study participant knew the treatment being administered. The study consisted of 3 phases: a
 screening phase, an open-label treatment phase consisting of 2 treatment periods, and a
 post-treatment phase. Subjects who met the prestudy eligibility criteria were randomly
 assigned to 1 of 2 treatment sequence groups. In each treatment period, subjects were
 admitted to the study facility the evening before study drug administration and housed
 through 48 hours after dosing with study drug. Subjects received levofloxacin as a single
 oral dose of 500 mg under both fed (within 10 minutes after completion of a high-fat,
 high-caloric breakfast) and fasted (10-hour overnight fast) conditions according to their
 randomized treatment sequence. Each dosing day was separated by a washout period of at least
 4 days. In each treatment period, pharmacokinetic blood samples were collected immediately
 prior to dosing and at 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 10, 14, 24, 30, 36, and 48 hours
 after dosing for determination of plasma concentrations of levofloxacin. Safety evaluations,
 including adverse event monitoring, standard clinical laboratory evaluations (hematology,
 serum chemistry, and urinalysis), vital sign monitoring, and physical examinations were
 performed on Days 1 and 3 of each treatment period. The post-treatment phase consisted of
 safety evaluations performed after collection of the final pharmacokinetic blood sampling in
 the second treatment period. Adverse events were monitored from the time of the first
 study-related procedure through completion of post-treatment study procedures, or until the
 time of early withdrawal from the study. Levofloxacin solution administered as 2 single oral
 doses of 500 mg each, 1 in each treatment period, administered at least 4 days apart.
Inclusion Criteria:

 -  Men and women

 -  Aged 18 to 55 years

 -  BMI between 18 and 30 kg/m2

 -  No prescription or over-the-counter medication for previous 14 days

 -  Negative tests for drug and alcohol abuse

 -  HIV, hepatitis B and hepatitis C

 -  and Healthy based on medical history, physical examination, 12-lead
 electrocardiograms, toxicology, antigen, antibody screens, and clinical laboratory
 evaluations

 Exclusion Criteria:

 -  Allergic reaction to quinolones

 -  clinically significant ECG or clinical laboratory abnormalities

 -  creatinine clearance <=80 mL/min

 -  acute illness within 7 days

 -  receipt of experimental drug or device within 60 days

 -  pregnant or breastfeeding